Efficacy and safety of recombinant thrombopoietin on adult severe primary immune thrombocytopenia

Abstract

Objective To study the effect and safety of recombinant thrombopoietin (rhTPO) therapy on adult severe primary immune thrombocytopenia (ITP). Methods Ninety-four adult patients with severe ITP were selected as research subjects and were divided into observation group and control group, according to the random number table method, with 47 cases in each group. The observation group was treated with rhTPO, and the control group was treated with glucocorticoid. The two groups were treated for 2 weeks. The efficacy, safety and incidence of adverse reactions were compared between the two groups after treatment. Results The effective rate of treatment in observation group (87.2%) was significantly higher than that in control group (63.8%), and the difference was statistically significant (P 0.05). The incidence of adverse reaction in observation group (8.5%) was lower than that in control group (12.5%), the difference was not statistically significant (P>0.05). Conclusions rhTPO has a significant effect on adult patients with severe ITP, which is superior to conventional glucocorticoid treatment, and has high safety and low incidence of adverse reactions. It is worthy of clinical promotion. Key words: Recombinant thrombopoietin; Primary immune thrombocytopenia; Efficacy; Safety